The first atrial septal defects (ASDs) were closed percutaneously in 1974 and reports about their closure published in 1976.1 In the 1980s the Rashkind occluder was introduced and revived the interest ...

Background Young patients suffering from cryptogenic stroke alongside a patent foramen ovale (PFO) are often considered for percutaneous device closure to reduce the risk of stroke recurrence.

Transcatheter patent foramen ovale (PFO) closure is a safe, effective, and highly successful procedure, associated with a low incidence of in-hospital complications and a low frequency of recurrent ...

From the Division of Cardiology, Washington Hospital Center, Washington, DC. Patent foramen ovales (PFOs) are common congenital cardiac defects that are more prevalent among patients experiencing ...

Background—The role of surgical closure of patent foramen ovale (PFO) for cerebral infarction (CI) or transient ischemic attack (TIA) resulting from paradoxical embolism is unclear, and its effect on.

PFO closure was recommended in systemic embolism without other embolic etiologies and in platypnea-orthodeoxia syndrome without other known causes of hypoxia. ... need for surgical procedures, ...

Patent foramen ovale (PFO) describes a valve in the interatrial septum that permits shunting of blood or thrombotic material between the atria. ... This high rate of technical failure may explain why ...